Taipei Exchange - Delayed Quote TWD

Li Kang Biomedical Co., Ltd. (6242.TWO)

41.95
0.00
(0.00%)
At close: 1:30:40 PM GMT+8
Loading Chart for 6242.TWO
  • Previous Close 41.95
  • Open 41.95
  • Bid 41.60 x --
  • Ask 42.00 x --
  • Day's Range 41.60 - 42.25
  • 52 Week Range 35.20 - 52.60
  • Volume 7,208
  • Avg. Volume 19,615
  • Market Cap (intraday) 1.334B
  • Beta (5Y Monthly) -0.02
  • PE Ratio (TTM) 16.71
  • EPS (TTM) 2.51
  • Earnings Date --
  • Forward Dividend & Yield 2.50 (6.13%)
  • Ex-Dividend Date Jun 20, 2024
  • 1y Target Est --

Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.

www.likangbio.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6242.TWO

View More

Performance Overview: 6242.TWO

Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6242.TWO
2.21%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
8.27%

1-Year Return

6242.TWO
14.26%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
2.03%

3-Year Return

6242.TWO
2.72%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
35.30%

5-Year Return

6242.TWO
86.62%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
94.21%

Compare To: 6242.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6242.TWO

View More

Valuation Measures

Annual
As of 5/9/2025
  • Market Cap

    1.33B

  • Enterprise Value

    985.82M

  • Trailing P/E

    16.98

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.31

  • Price/Book (mrq)

    1.56

  • Enterprise Value/Revenue

    1.74

  • Enterprise Value/EBITDA

    8.78

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.62%

  • Return on Assets (ttm)

    6.04%

  • Return on Equity (ttm)

    10.37%

  • Revenue (ttm)

    565.52M

  • Net Income Avi to Common (ttm)

    77.02M

  • Diluted EPS (ttm)

    2.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    454.4M

  • Total Debt/Equity (mrq)

    10.74%

  • Levered Free Cash Flow (ttm)

    -13.73M

Research Analysis: 6242.TWO

View More

Company Insights: 6242.TWO

Research Reports: 6242.TWO

View More

People Also Watch